GlassScriptPhysician profile
Gina Marrero
NPI 1205835790
$754.73
in general payments reported to CMS, 2019-2025
11 companies · $25.98 in 2025
The $25.98 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.89 · 2021: $266 · 2022: $168 · 2023: $163 · 2024: $59.46 · 2025: $25.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $237.17 | 2021-2022 | |
| Genzyme Corporation | $116.34 | 2022-2024 | |
| Biofrontera INC. | $88.86 | 2019-2022 | |
| Pfizer INC. | $79.67 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $59.16 | 2023-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $50.16 | 2023 | Absorica Ld, Winlevi |
| Epi Health, LLC | $40.96 | 2021-2022 | |
| Amgen INC. | $25.98 | 2025 | Otezla |
| Verrica Pharmaceuticals INC. | $24.16 | 2023 | Ycanth |
| Aroa Biosurgery Incorporated | $17.16 | 2022 | |
| Lilly USA, LLC | $15.11 | 2023 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Marrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.